Altered serum levels of IL-33 in patients with advanced systolic chronic heart failure: correlation with oxidative stress

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Zhang, Hai Feng ^a   Xie, Shuang Lun ^a   Chen, Yang Xin ^a   Mai, Jing Ting ^a   Wang, Jing Feng ^a   Zhu, Wa Li ^b   Zhu, Li Guang ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Chronic heart failure; Interleukin 33; Oxidative stress; Soluble ST2

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN II; BIOLOGICAL MARKER; CELL PROTEIN; INTERLEUKIN 33; MALONALDEHYDE; SOLUBLE ST2 PROTEIN; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ADVANCED SYSTOLIC CHRONIC HEART FAILURE; AGED; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; UPREGULATION;

AGED; CASE-CONTROL STUDIES; CHRONIC DISEASE; FEMALE; HEART FAILURE; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; OXIDATIVE STRESS; SYSTOLE;

EID: 84861938177     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-120     Document Type: Article

References (33)

1. Krum H, Abraham WT. Heart failure. Lancet 2009, 373:941-955. 10.1016/S0140-6736(09)60236-1, 19286093.
2. Redfield MM, Jacobsen SJ, Burnett JC, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003, 289:194-202. 10.1001/jama.289.2.194, 12517230.
3. Seddon M, Looi YH, Shah AM. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart 2007, 93:903-907. 10.1136/hrt.2005.068270, 1994416, 16670100.
4. Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, Calori G, Alfieri O, Margonato A. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006, 48:992-998. 10.1016/j.jacc.2006.03.060, 16949492.
5. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010, 10:103-110. 10.1038/nri2692, 20081870.
6. Kunes P, Holubcova Z, Kolackova M, Krejsek J. Interleukin-33, a novel member of the IL-1/IL-18 cytokine family, in cardiology and cardiac surgery. Thorac Cardiovasc Surg 2010, 58:443-449. 10.1055/s-0030-1250436, 21113894.
7. Iwahana H, Yanagisawa K, Ito-Kosaka A, Kuroiwa K, Tago K, Komatsu N, Katashima R, Itakura M, Tominaga S. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem 1999, 264:397-406. 10.1046/j.1432-1327.1999.00615.x, 10491084.
8. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007, 117:1538-1549. 10.1172/JCI30634, 1865027, 17492053.
9. Pascual-Figal DA, Ordonez-Llanos J, Tornel PL, Vazquez R, Puig T, Valdes M, Cinca J, de Luna AB, Bayes-Genis A. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol 2009, 54:2174-2179. 10.1016/j.jacc.2009.07.041, 19942089.
10. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003, 107:721-726. 10.1161/01.CIR.0000047274.66749.FE, 12578875.
11. Reddy VS, Prabhu SD, Mummidi S, Valente AJ, Venkatesan B, Shanmugam P, Delafontaine P, Chandrasekar B. Interleukin-18 induces EMMPRIN expression in primary cardiomyocytes via JNK/Sp1 signaling and MMP-9 in part via EMMPRIN and through AP-1 and NF-kappaB activation. Am J Physiol Heart Circ Physiol 2010, 299:H1242-H1254. 10.1152/ajpheart.00451.2010, 2957343, 20693392.
12. Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J, Lee RT. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2009, 2:684-691. 10.1161/CIRCHEARTFAILURE.109.873240, 19919994.
13. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119:e391-479.
14. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005, 112:e154-235. 10.1161/CIRCULATIONAHA.105.167586, 16160202.
15. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology 2007, 18:800-804. 10.1097/EDE.0b013e3181577654, 18049194.
16. Davidson MM, Nesti C, Palenzuela L, Walker WF, Hernandez E, Protas L, Hirano M, Isaac ND. Novel cell lines derived from adult human ventricular cardiomyocytes. J Mol Cell Cardiol 2005, 39:133-147. 10.1016/j.yjmcc.2005.03.003, 15913645.
17. Pastorelli L, Garg RR, Hoang SB, Spina L, Mattioli B, Scarpa M, Fiocchi C, Vecchi M, Pizarro TT. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci U S A 2010, 107:8017-8022. 10.1073/pnas.0912678107, 2867895, 20385815.
18. Castro P, Vukasovic JL, Chiong M, Diaz-Araya G, Alcaino H, Copaja M, Valenzuela R, Greig D, Perez O, Corbalan R, et al. Effects of carvedilol on oxidative stress and chronotropic response to exercise in patients with chronic heart failure. Eur J Heart Fail 2005, 7:1033-1039. 10.1016/j.ejheart.2004.11.009, 16227141.
19. Nie F, Zhang X, Qi Q, Yang L, Yang Y, Liu W, Lu N, Wu Z, You Q, Guo Q. Reactive oxygen species accumulation contributes to gambogic acid-induced apoptosis in human hepatoma SMMC-7721 cells. Toxicology 2009, 260:60-67. 10.1016/j.tox.2009.03.010, 19464570.
20. Larsson T, Nisbeth U, Ljunggren O, Jüppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003, 64:2272-2279. 10.1046/j.1523-1755.2003.00328.x, 14633152.
21. Ohno T, Oboki K, Kajiwara N, Morii E, Aozasa K, Flavell RA, Okumura K, Saito H, Nakae S. Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages. J Immunol 2009, 183:7890-7897. 10.4049/jimmunol.0802449, 19933859.
22. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479-490. 10.1016/j.immuni.2005.09.015, 16286016.
23. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A 2009, 106:9021-9026. 10.1073/pnas.0812690106, 2690027, 19439663.
24. May LT, Ndubuisi MI, Patel K, García D. Interleukin-6 chaperones in blood. Ann N Y Acad Sci 1995, 762:120-128.
25. Dhillon OS, Narayan HK, Quinn PA, Squire IB, Davies JE, Ng LL. Interleukin 33 and ST2 in non-ST-elevation myocardial infarction: comparison with global registry of acute coronary events risk scoring and NT-proBNP. Am Heart J 2011, 161:1163-1170. 10.1016/j.ahj.2011.03.025, 21641364.
26. Zhao W, Hu Z. The enigmatic processing and secretion of interleukin-33. Cell Mol Immunol 2010, 4:260-262.
27. Bartunek J, Delrue L, Van Durme F, Muller O, Casselman F, De Wiest B, Croes R, Verstreken S, Goethals M, de Raedt H, et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol 2008, 52:2166-2174. 10.1016/j.jacc.2008.09.027, 2637465, 19095135.
28. Mok MY, Huang FP, Ip WK, Lo Y, Wong FY, Chan EY, Lam KF, Xu D. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) 2010, 49:520-527.
29. Mu R, Huang HQ, Li YH, Li C, Ye H, Li ZG. Elevated serum interleukin 33 is associated with autoantibody production in patients with rheumatoid arthritis. J Rheumatol 2010, 37:2006-2013. 10.3899/jrheum.100184, 20682660.
30. Hong YS, Moon SJ, Joo YB, Jeon CH, Cho ML, Ju JH, Oh HJ, Heo YJ, Park SH. Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. J Korean Med Sci 2011, 26:1132-1139. 10.3346/jkms.2011.26.9.1132, 3172648, 21935266.
31. Kakkar R, Hei H, Dobner S, Lee RT. Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J Biol Chem 2012, 9:6941-6948.
32. Chong AY, Blann AD, Patel J, Freestone B, Hughes E, Lip GY. Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation 2004, 110:1794-1798. 10.1161/01.CIR.0000143073.60937.50, 15364797.
33. Manzano-Fernandez S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol 2011, 107:259-267. 10.1016/j.amjcard.2010.09.011, 3218083, 21211603.